QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Q32 Bio Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$7.79+0.27 (+3.59%)
Close on Oct 19, 2026
- Market cap
- $158.47M
- P/E (TTM)
- 3.2
- Dividend yield
- –
Q32 Bio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Q32 Bio | Industry median |
|---|---|---|
| Market Cap | $231.90M | $166.30M |
| Enterprise Value | $125.63M | $87.12M |
| PB Ratio | 2.19 | 2.03 |
| P/TBV Ratio | 2.19 | 2.31 |
Enterprise value
| Measure | Q32 Bio | Industry median |
|---|---|---|
| EV / EBITDA | 5.85 | 14.69 |
| EV / EBIT | 5.85 | 18.47 |
Income (trailing twelve months)
| Measure | Q32 Bio | Industry median |
|---|---|---|
| Operating Income | $21.46M | -$21.49M |
| Net Income | $33.79M | -$22.46M |
| EBITDA | $21.46M | -$17.14M |
Returns
| Measure | Q32 Bio | Industry median |
|---|---|---|
| Return on Equity (ROE) | 72.1% | -53.2% |
| Return on Assets (ROA) | 37.1% | -41.0% |
| Return on Capital Employed (ROCE) | 19.4% | -38.0% |
Growth
| Measure | Q32 Bio | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | 155.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 81.9% | 6.42% |
Balance sheet
| Measure | Q32 Bio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $106.27M | $62.64M |
| Net Cash (Debt) | $106.27M | $15.77M |
| Net Cash Per Share | $3.57 | $0.66 |
| Equity (Book Value) | $105.91M | $48.61M |
| Book Value Per Share | $3.56 | $1.36 |
| Tangible Book Value | $105.91M | $23.01M |
| Working Capital | $104.25M | $75.09M |
Financial position
| Measure | Q32 Bio | Industry median |
|---|---|---|
| Current Ratio | 20.30 | 3.30 |
| Quick Ratio | 19.68 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Q32 Bio | Industry median |
|---|---|---|
| Operating Cash Flow | -$19.83M | -$12.39M |
Efficiency
| Measure | Q32 Bio | Industry median |
|---|---|---|
| Profits Per Employee | $1.41M | -$705.27K |
| Employee Count | 24 | 74 |
Dividends and yields
| Measure | Q32 Bio | Industry median |
|---|---|---|
| Earnings Yield | 14.6% | -22.8% |
| Buyback Yield | -4.47% | -0.73% |
| Shareholder Yield | -4.47% | 0.00% |
Shares
| Measure | Q32 Bio | Industry median |
|---|---|---|
| Shares Outstanding | 29,769,500 | 58,139,000 |
| Shares Change (YoY) | 21.8% | 11.1% |
| Shares Change (QoQ) | 62.3% | 0.54% |
| Float | 21,147,800 | 49,154,900 |
| Shares Held by Insiders | 29.0% | 11.6% |
| Shares Held by Institutions | 74.6% | 59.4% |
Taxes
| Measure | Q32 Bio | Industry median |
|---|---|---|
| Income Tax | $0 | $89.00K |
Scores
| Measure | Q32 Bio | Industry median |
|---|---|---|
| Altman Z-Score | 12.98 | -0.27 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Q32 Bio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.